We report a high incidence (19.5%) of autoimmune hemolytic anemia (AIHA) in 41 patients with SCID who underwent a T cell-depleted haploidentical transplant. Other than infections, AIHA was the most common posttransplant complication in this patient cohort. Clinical characteristics and treatment of eight patients who developed AIHA at a median of 8 months after the first T cell-depleted transplant are presented. All patients had warm-reacting autoantibodies, and two of eight had concurrent cold and warm autoantibodies. Clinical course was most severe in two patients who had cold and warm autoantibodies. Five patients received specific therapy for AIHA. Successful taper off immunosuppressive therapy for AIHA coincided with T cell reconstitution. Delayed reconstitution of T cell immunity, due to T cell depletion, immunosuppressive conditioning and CsA, as well as paucity of regulatory T cells, are the likely explanations for the occurrence of AIHA in our patient cohort. Screening of the population at risk may prevent morbidity and mortality from AIHA.
gone a parental T cell-depleted haploidentical transplant, the incidence of AIHA was 19.5%, which is higher than previously described. 4 In this report, we analyze risk factors for the development of AIHA and present clinical characteristics, therapy and outcome of eight patients with AIHA.
Patients and methods
Forty-one patients who received T cell-depleted haplocompatible parental BMT for SCID between July 1983 and May 1998 at the University of California in San Francisco (UCSF) were included in the study, with the mean followup of 69 months. Eight of them developed AIHA. Patients were classified as having AIHA only if they met all of the following criteria: (1) positive DAT; (2) positive eluate with broad specificity; and (3) clinical evidence of hemolytic anemia indicated by at least two of the following findings: decreased hemoglobin, increased MCV, increased reticulocytes, and increased bilirubin.
BM was the source of stem cells for 34 patients who were transplanted prior to October 1996. T cell depletion of bone marrow was done using soybean agglutinin (SBA) and two cycles of sheep erythrocyte (SRBC) rosetting as previously described. 5 PBSC transplants were done for eight patients transplanted since October 1996. PBSC processing included CD34-enrichment using the Baxter Isolex300 (Baxter, Deerfield, IL, USA) immunomagnetic bead system and subsequent T cell-depletion using one to two cycles of OKT3 monoclonal antibody with immunomagnetic beads, as previously described. 6 Clinical information was obtained from the UCSF pediatric bone marrow transplant data base, blood bank data base, review of laboratory results, and chart review. Details of conditioning regimens and anti-GVHD prophylaxis are outlined in Table 1 . T cell reconstitution was defined as age appropriate T cell number and normal lymphocyte proliferation in response to PHA and alloantigen (MLR), measured by incorporation of 3 H-thymidine, as previously described. 7 B cell reconstitution was defined as normal IgM and isohemagglutinin titers.
Serological testing
Serological tests were performed as outlined in the Technical Manual of the American Association of Blood Banks. 8 The DAT was performed with a commercial polyspecific antihuman globulin reagent (Immucor, Norcross, GA, USA). Further testing with anti-IgG and anti-C3d monospecific reagents was performed to demonstrate the presence of specific immunoglobulin and/or complement. Antibodies were eluted using a commercial acid elution test (Gamma Biologicals, Houston, TX, USA). Serum antibody screening and identification studies were performed using PEG (Gamma Biologicals) according to the manufacturer's directions to detect free antibody in the patients' serum. Monospecific anti-IgG (Immunocor) was used for all IATs. Appropriate allo-or autoabsorption was done to determine whether underlying alloantibodies were present, as described in the Technical Manual. 8 Statistical analysis included descriptive statistics, the two-tailed Fisher's exact test and chi-square when testing associations of independent variables, and the two-tailed ttest for the comparison of means. Variables affecting the development of AIHA were sought using a logistic regression model. Likelihood ratio (LR) and the P value are presented. All data analyses and tests were performed using the SPSS statistical program (SPSS, Chicago, IL, USA, version 6.1 for Windows).
Results

Risk factors
Eight of 41 (19.5%) patients with SCID who underwent a T cell-depleted parental haploidentical transplant developed AIHA. AIHA occurred in one patient before transplant (UPN 134) and recurred 6 months after her first BMT. Seven other patients developed AIHA at a median of 8 months (range 6-63 months) after the first T cell-depleted transplant. Repeated T cell-depleted transplants/boosts were done in 16 patients, due to failure of engraftment or incomplete immune reconstitution (criteria for repeated transplants were previously described). 7 Median follow-up of living patients was 103 months (range 12 to 204 months). Table 1 presents clinical characteristics of 41 patients with SCID who underwent a T cell-depleted transplant. Patients with AIHA were more likely to have received PBSC than those who did not develop AIHA (P = 0.02). Four of eight patients who developed AIHA received T cell-depleted PBSC transplants (including patient UPN 140 who developed AIHA after her first PBSC boost). Three of four patients who received a PBSC transplant also received CsA for GVHD prophylaxis, and two other patients received CsA for GVHD therapy. In a multivariate model that included maternal engraftment (yes or no), GVHD prophylaxis (yes or no), age at BMT (Ͻ6 months or у6 months), diagnosis (T-B− SCID, T-B+ SCID, or other), GVHD (yes or no), conditioning regimen (no conditioning or any conditioning regimen), ABO compatibility between donor and recipient (identical or any other combination) and source of stem cells (BM or peripheral blood), only peripheral blood as the stem cell source was found to be related to an increased risk of development of AIHA (LR = 9.3, P = 0.02).
Serologic testing
The serologic data at diagnosis of AIHA are shown in Table  2 . All patients had strongly positive DAT and IAT. An eluate prepared from the cells of patients was strongly positive with broad reactivity. Two patients had concurrent coldreacting antibodies with no apparent specificity. One patient's antibody was reactive only at 4°C (UPN 140); the other patient's antibody showed a thermal amplitude up to 30°C (UPN 219). Two patients had allo-antibodies, one (UPN 134) had a historical anti-E that was also present at the time of AIHA diagnosis, and the other patient (UPN 219) developed detectable allo anti-E and -c later in the course of her treatment. 
Clinical characteristics and therapy of patients with AIHA
:CD8
+ ratio was abnormal in 75% of patients, absolute CD19
+ count was abnormal in 83% of patients, response to MLR was abnormal in 75% of patients, and response to PHA was abnormal in 88% of patients. Table 4 shows clinical characteristics of eight patients who developed AIHA, their treatment and outcome. Three patients (UPN 164, 296 and 318) did not receive specific therapy for AIHA. One patient (UPN 164) was treated with supportive transfusions and was not placed on immunosuppressive therapy due to CMV infection; another (UPN 296) had mild, compensated hemolysis and did not require specific treatment, and the third patient (UPN 318) died at presentation of AIHA due to low hemoglobin and cardiorespiratory failure. Two patients with warm and cold autoantibodies also had other immune cytopenias. The first (UPN 140) had transient immune thrombocytopenia and neutropenia which developed prior to the development of AIHA and which responded to steroids and CsA. This Table 3 Immune function at the time of AIHA diagnosis T cell reconstitution occurred in three of four surviving patients, and these patients have been successfully tapered off immunosuppressive therapy.
Discussion
The incidence of AIHA of 19.5% in patients undergoing T cell-depleted transplant for SCID is higher than previously reported. Drobyski et al 4 described AIHA in 5% of patients who survived at least 6 months post T cell-depleted BMT, and Godder et al 9 described Coombs positive AIHA in 7.5% of patients receiving T cell-depleted haploidentical BMT. The incidence of AIHA in our patients who underwent T cell-depleted haploidentical BMT for disorders other than SCID is similar to the one reported in the literature, as 6% of patients who survived at least 6 months after the transplant developed AIHA (data not shown). It is likely that the overall incidence of AIHA in BMT patients is under-reported, as mild cases of compensated hemolysis may go unrecognized unless routine screening is done.
Patients with SCID, who do not receive myeloablative conditioning, usually achieve full donor chimerism for T lymphocytes; however, B lymphocytes and red blood cells often remain of host origin. 10, 11 During the reconstitution of the immune system, after T cell-depleted transplants for SCID, multiple immune defects are present, including decreased cytokine production (IL-6, IL-4), lack of specific antibody production, and deficits in T cell/B cell cooperation. 12 Kent et al, 11 Ghory et al 13 and Hammarstrom et al 14 described the development of multiple monoclonal serum immunoglobulins 48-63 days following T celldepleted transplants in SCID patients, and their disappearance after reconstitution of T cell immunity. 11, 13 Similarly, Chen et al 3 reported paraproteins in six of nine patients with post-transplant AIHA, which is more common than in other post-transplant patients.
14 Due to the retrospective nature of our study we do not have information on immunoelectrophoresis in our patients.
In our patient cohort, at the time of AIHA development, seven of eight patients had confirmed donor T cell engraftment and only two of four evaluated patients had confirmed donor B cell engraftment. However, T cell function was abnormal in all patients at the time of AIHA diagnosis, with a paucity of CD4 + and/or CD8 + cells and abnormal proliferative responses. We hypothesize that the paucity of regulatory T cells in our patients may have accounted for the emergence of unregulated immunoglobulin-producing B cell clones, and delayed T cell reconstitution may have accounted for their persistence. Indeed, after reconstitution of T cell immunity, a reduction of immunosuppressive therapy for AIHA was possible. Our patients were at particular risk for delayed T cell reconstitution due to T cell depletion, immunosuppressive conditioning, and CsA, which was given either as prophylaxis or for treatment of GVHD. Although the numbers are small, and this finding needs to be confirmed in larger series, we described a significantly higher risk of AIHA in patients who received T cell-depleted PBSC when compared to those who received BMT (50% vs 12.5%, P = 0.02). A possible explanation might be a more effective T cell depletion using OKT3 monoclonal antibodies and immunomagnetic beads than with SBA and SRBC. This could have resulted in more profound T cell dysfunction (mean number of infused CD3 cells in PBSC transplants was 3.4 × 10 4 /kg, as previously described). 6 Alternatively, the vastly different T cell depletion techniques could have resulted in unique residual T cell subsets.
Immunosuppressive therapy with CsA and steroids was effective in the treatment of most patients with AIHA, again indicating T cell dysfunction as the likely cause. Two patients who had concurrent cold-reacting autoantibodies and other immune cytopenias had a severe clinical course and required additional treatments as described in Table 4 and Results. Treatment of AIHA was lengthy, and successful taper of immunosuppression was possible in patients who achieved T cell reconstitution. In this population of SCID patients, AIHA was more common than GVHD. Being that AIHA significantly contributes to the morbidity and mortality of patients undergoing T cell-depleted transplants for SCID, we have initiated monthly screening with DAT and IAT of all patients who undergo T cell-depleted transplantation, until the reconstitution of their T cell immunity is achieved.
